Publications

In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia: SENTRY Surveillance 2017-2018 Results from the United States. Lead author: S Paukner, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster # 703

In Vitro Activity of the β-lactamase Inhibitor QPX7728 In Combination with Several β-lactams against Acinetobacter baumannii (AB) and Pseudomonas aeruginosa (PSA). Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #681

Comparison of cefepime-zidebactam (WCK 5222), ceftazidime-avibactam, and ceftolozane-tazobactam tested against Gram-negative organisms causing pneumonia in United States hospitals in 2018. Lead author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #2214

Minocycline Activity against Stenotrophomonas maltophilia Isolated from Patients in US Hospitals. Lead author: D Shortridge, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1584

Comparison of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Activities when Tested against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections. Lead author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster # 1436

Delafloxacin Activity against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014-2018). Lead author: D Shortridge, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1582

Activity of a Novel Polymyxin Analog, QPX9003, Tested against Resistant Gram-Negative Pathogens, Including Carbapenem-Resistant Acinetobacter, Enterobacterales, and Pseudomonas. Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #690

In vitro Activity of Omadacycline against Recent (2018) Bacterial Pathogens Obtained from the United States and Europe from Skin and Skin Structure, Respiratory, and Urinary Tract Infections. Lead author: MD Huband, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #665

Activity of Novel β-Lactamase Inhibitor QPX7728 Combined with β-Lactam Agents When Tested against Carbapenem-Resistant Enterobacterales (CRE) Isolates. Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #677

Ceftobiprole Activity against Pathogens Causing Bacterial Skin and Skin Structure Infections in the United States from 2016 through 2018. Lead author: LR Duncan, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster# T-67

In Vitro Activity of KHP-3757 and Comparators against Recent and Molecularly Characterized Pseudomonas aeruginosa Isolates from a Global Surveillance Program. Lead author: MD Huband, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster

Activity of KBP-7072 against Recent and Molecularly Characterized Acinetobacter baumannii Isolates. Lead author: MD Huband, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster # W-69

Ceftibuten-Avibactam Activity against β-Lactam-Resistant Enterobacteriaceae Clinical Isolates. Lead author LR Duncan, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-717

Cefepime-Zidebactam (WCK 5222) Activity against Clinical Isolates of Non-Fermentative Gram-Negative Bacilli Collected Worldwide in 2018. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-730

Activity of Meropenem-Vaborbactam and Characterization of Carbapenem Resistance Mechanisms among Carbapenem-Resistant Enterobacteriaceae from United States Hospitals (2016-2017). Lead author: M Castanheira, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-594

Ceftibuten-Clavulanate Activity against Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Saturday-AAR-780

Cefepime-Zidebactam (WCK 5222) Activity when Tested against Enterobacterales Isolated from Patients Hospitalized in the United States and Latin America in 2018. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA
# Saturday-AAR-754

In Vitro Activity of Tedizolid and Comparator Agents against Gram-Positive Isolates Causing Bloodstream Infections in US and European Hospitals (2018). Lead Author: C Carvalhaes, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
#Saturday-AAR-612

Tedizolid In Vitro Activity against a Collection of Multidrug-Resistant Gram-Positive Clinical Isolates from US Medical Centers (2017-2018). Lead author: C Carvalhaes, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Saturday-AAR-611

Monitoring the In Vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, against a Current Collection of Surveillance Enterobacterales Clinical Isolates (2018). Lead author: RE Mendes, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
#Saturday-AAR-777

Ceftobiprole Activity against Pathogens Causing Bacterial Skin and Skin Structure Infections in the United States from 2016 through 2018. Lead author: LR Duncan, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Saturday-AAR-607

Activity of Investigational Polymyxin-B-Like Compound (SPR206) against Set of Gram-Negative Bacilli Responsible for Human Infections. Lead author: SJR Arends, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Friday-AAR-796

In Vitro Activity of Omadacycline and Comparators against Gram-positive and -Negative Isolates Collected from Patients in United States Medical Centers (2018): SENTRY Surveillance Program Results. Lead author: MD Huband presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Friday-AAR-540

Update on the In Vitro Activity of Dalbavancin against Indicated Species (Staphylococcus aureus, Enterococcus Faecalis, β-Hemolytic Streptococci, and Streptococcus anginosus Group) Collected from United States Hospitals in 2017-2018. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Friday-AAR-542

Comparison of the in vitro susceptibility of ceftolozane-tazobactam to the cumulative susceptibility rates of standard antibiotic combinations when tested against Pseudomonas aerugionsa from ICU patients with bloodstream infections or pneumonia. by Shortridge D, Pfaller MA, Arends SJR, Raddatz J, DePestel DD and Flamm RK. published in Open Forum Infect. Dis. 20196 (6): ofz240

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). by Sader HS, Flamm RK, Carvalhaes CG and Castanheira M. published in Diagn. Microbiol. Infect. Dis.: in press, 2020; 96: 114833

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17). by Carvalhaes CG, Sader HS, Flamm RK and Mendes RE. published in J. Antimicrob. Chemother. 2019; 74 (7): 1928-1933

In vitro activity of tedizolid in comparison with other oral and intravenous agents against a collection of community-acquired methicillin-resistant Staphylococcus aureus (2014-2015) in the United States. by Pfaller MA, Sader HS, Rhomberg PR, Flamm RK and Mendes RE. published in Microb. Drug Resist. 2019; 25 (6), 938-943

Comparative activity of ceftazidime-avibactam and ceftolozane-tazobactam against Enterobacteriaceae isolates producing extended-spectrum beta-lactamases from United States hospitals. by Castanheira M, Doyle TB, Mendes RE and Sader HS. published in Antimicrob. Agents Chemother. 2019; 63 (7), e00160

Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015). by Pfaller MA, Sader HS, Shortridge D, Castanheira M, Flamm RK and Mendes RE. published in J. Chemother. 2019; 13: 1-7

In vitro activity of plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions. by Castanheira M, Davis AP, Serio AW, Krause KM and Mendes RE. published in Diagn. Microbiol. Infect. Dis. 2019; 94 (1): 73-77.

In Vitro Activity of BWC0977 (a Novel Bacterial Topoisomerase Inhibitor) and Comparators against Recent Clinical and Molecularly Characterized Enterobacteriaceae and Non-Fermenter Isolates from the United States and Europe. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1847

In Vitro Activity of Omadacycline and Comparators against Recent Gram-Positive and -Negative Clinical Isolates Collected in 2018 from Patients in European Medical Centres: SENTRY Surveillance Program Results. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1876

In Vitro Activity of the Extended-Spectrum β-Lactamase Inhibitor Enmetazobactam (formerly AAI101), in Combination with Cefepime, against 90 Moleculary Characterized Enterobacteriaceae Isolates Expressing a Variety of Non-β-Lactam Resistance Mechanisms. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1170

Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Patients at Risk of Infections Caused by Resistant Gram-Negative Pathogens. Lead author: D Shortridge, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1191

In vitro activity of tedizolid against gram-positive cocci isolates from patients hospitalized with pneumonia in the United States and Europe, 2014-2016. by Bensaci M, Tan C, Pfaller MA and Mendes RE published in Journal Infect Diseases and Treatment. 2018; 4 (1): 2

In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016). by Duncan LR, flamm RK, Sader HS and Mendes RE published in Diagn. Microbiol. Infect. Dis.: in press, 2018.

Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. by Castanheira M, Deshpande LM, Woosley LN, Serio AW, Krause KM and Flamm RK. published in J. Antimicrob. Chemother.: in press, 2018.

Analysis of Oritavancin In Vitro Activity against Enterococcal Isolates from US Medical Centers and Resistant Subsets. Lead author: RE Mendes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, Lisbon, Portugal
#116

Activity of Meropenem-Vaborbactam and Comparator Agents against Multidrug-Resistant Enterobacteriaceae Isolates from the United States Analyzed by Site of Infection. Lead author: M Castanheira, presented at ESMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#117

Tedizolid In Vitro Activity against a Contemporary Challenge Collection of Multidrug-Resistant Enterococcal Clinical Isolates. Lead author: CG Carvalhaes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#111

In Vitro Activity Evaluation of a Next-Generation Polymyxin, SPR206, against Non-Fermentative Gram-Negative Bacilli Responsible for Human Infections. Lead author: RE Mendes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#80

Activity of an Investigational Polymyxin-B-Like Compound (SPR206) against a Set of Enterobacteriaceae Organisms Responsible for Human Infections. Lead author: RE Mendes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#81

Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa. by Sader HS, Flamm RK, Dale GE, Rhomberg PR and Castanheira M published in J Antimicrob Chemother. 2018; 73: 2400-2404

Delafloxacin in vitro broth microdilution and disk diffusion antimicrobial susceptibility testing guidelines: Susceptibility breakpoint criteria and quality control ranges for an expanded spectrum anionic fluoroquinolone. by Pfaller MA, Flamm RK, McCurdy SP, Pillar CM, Shortridge D and Jones RN published in J. Clin. Microbiol. 2018; 56 (8): e00339

In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary Multidrug-Resistant Streptococcus pneumoniae (2014-2017): Results from the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-397

Activity of Plazomicin and Comparator Agents Tested against Contemporary Clinical Isolates Collected Worldwide. Lead author: M Castanheira, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-645

In Vitro Activity of Tedizolid and Comparator Agents Tested against Gram-Positive Isolates Causing Serious Infections in Hospitalized Patients in the United States and Europe. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-453

In Vitro Activity of a Novel Extended-Spectrum β-Lactamase Inhibitor, AAI101, in Combination with Cefepime, against Enterobacteriaceae Isolates Collected during 2016. Lead author: MD Huband, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-601

In vitro activity of plazomicin against Gram-negative and Gram-positive isolates collected from United States hospitals and comparative activity of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes. by Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM and Flamm RK published in Antimicrob. Agents Chemother. 2018; 62 (8): e00313